David Porter, MD, the director of cell therapy and transplant at Penn Medicine, also summed up his main message regarding the current state of the field in general.
David L. Porter, MD
Advertisement
Articles by David L. Porter, MD
The director of cell therapy and transplant at Penn Medicine also summed up his main message regarding the current state of the field in general.
The director of cell therapy and transplant at Penn Medicine discussed progress made and experienced gained for the field of cell therapy for autoimmune disease in 2024.
The director of Cell Therapy and Transplant at Penn Medicine discussed his outlook on CAR T-cell therapy research and the future.
The director of Cell Therapy and Transplant at Penn Medicine discussed important considerations with administering CAR-T in a new field.
The director of Cell Therapy and Transplant at Penn Medicine discussed how experience with CAR T in oncology has enabled the use of the technology in autoimmune diseases.
The director of Cell Therapy and Transplant at Penn Medicine discussed the potential of CAR T-cell therapy to benefit patients with diseases including Lupus nephritis.
The director of cell therapy and transplant at Penn Medicine discussed the seminar he gave at the inaugural Cell Therapy for Autoimmune Disease Summit.
In this review, we will describe the mechanism of action of CAR T cells, discuss outcomes of current clinical trials, and highlight emerging directions for this exciting approach to cancer treatment.
Advertisement
Latest Updated Articles
David Porter, MD, on Adopting CAR T-Cell Therapy for Autoimmune DiseasePublished: February 18th 2024 | Updated:
David Porter, MD, on Progress With Cross-Disciplinary Collaboration in Cell Therapy for Autoimmune DiseasePublished: January 23rd 2025 | Updated:
David Porter, MD, on Enabling the Expansion of CAR T to Autoimmune DiseasesPublished: March 2nd 2024 | Updated:
The Promise of Chimeric Antigen Receptor T-Cell TherapyPublished: October 15th 2016 | Updated:
